Advances in FGFs for diabetes care applications
Yinai Liu1, Qianqian Chen1, Yaoqi Li1
1Institute of Life Sciences & Biomedicine Collaborative Innovation Center of Zhejiang Province, College of Life and Environmental Science, Wenzhou University, Wenzhou 325035, China.
Life Sciences
|September 30, 2022
Summary
Fibroblast growth factors (FGFs) show promise for treating diabetes by safely lowering blood sugar. These FGFs offer a new approach to manage hyperglycemia and overcome insulin resistance, addressing limitations of current treatments.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Diabetes mellitus (DM) is a growing global health threat with increasing prevalence.
- Current treatments like insulin can cause hypoglycemia and insulin resistance.
- There is an urgent need for safer, more effective diabetes medications.
Purpose of the Study:
- To review the physiological and pharmacological roles of fibroblast growth factors (FGFs) in diabetes treatment.
- To explore the potential of FGFs as novel therapeutic agents for diabetes care and prevention.
Main Methods:
- Literature review of research on FGFs (FGF1, FGF19, FGF21, FGF23) and their effects on glucose metabolism.
- Analysis of studies investigating FGFs for hyperglycemia and insulin resistance.
Main Results:
- Certain FGFs (FGF1, FGF19, FGF21) demonstrate safe and effective hyperglycemia reduction.
- FGF23 is linked to diabetes and its complications, offering a new avenue for blood glucose regulation.
- FGFs present a potential solution to insulin tolerance associated with traditional therapies.
Conclusions:
- FGFs represent a promising class of compounds for diabetes management.
- Further research into FGFs could lead to innovative treatments for diabetes care and prevention.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
339
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
339
01:22Diabetes Mellitus: Type 2 and Gestational
2.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.7K
01:22Diabetes Mellitus: Overview and Type I Subtype
3.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.0K
01:20Pathophysiology of Diabetes
1.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.1K
01:15Diabetes: Symptoms, Diagnosis, and Complications
662
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
662
01:24Glucagon-like Receptor Agonists
389
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
389